Turner JR - Search Results

1

Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction.

Christian JB, Finkle JK, Ky B, Douglas PS, Gutstein DE, Hockings PD, Lainee P, Lenihan DJ, Mason JW, Sager PT, Todaro TG, Hicks KA, Kane RC, Ko HS, Lindenfeld J, Michelson EL, Milligan J, Munley JY, Raichlen JS, Shahlaee A, Strnadova C, Ye B, Turner JR. Christian JB, et al. Among authors: turner jr. Am Heart J. 2012 Dec;164(6):846-55. doi: 10.1016/j.ahj.2012.09.001. Epub 2012 Oct 26. Am Heart J. 2012. PMID: 23194484 Free PMC article. Review.

2

Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development.

Min SS, Turner JR, Nada A, DiMino TL, Hynie I, Kleiman R, Kowey P, Krucoff MW, Mason JW, Phipps A, Newton-Cheh C, Pordy R, Strnadova C, Targum S, Uhl K, Finkle J. Min SS, et al. Among authors: turner jr. Am Heart J. 2010 May;159(5):716-29. doi: 10.1016/j.ahj.2010.02.004. Am Heart J. 2010. PMID: 20435178 Review.

3

Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration.

Newby LK, Rodriguez I, Finkle J, Becker RC, Hicks KA, Hausner E, Chesler R, Harper C, Targum S, Berridge BR, Lewis E, Walker DB, Dollery C, Turner JR, Krucoff MW. Newby LK, et al. Among authors: turner jr. Am Heart J. 2011 Jul;162(1):64-73. doi: 10.1016/j.ahj.2011.04.005. Am Heart J. 2011. PMID: 21742091 Review.

4

Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium.

Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Sager PT, et al. Among authors: turner jr. Am Heart J. 2014 Mar;167(3):292-300. doi: 10.1016/j.ahj.2013.11.004. Epub 2013 Dec 2. Am Heart J. 2014. PMID: 24576511 Free article.

5

Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium.

Sager P, Heilbraun J, Turner JR, Gintant G, Geiger MJ, Kowey PR, Mansoor GA, Mendzelevski B, Michelson EL, Stockbridge N, Weber MA, White WB. Sager P, et al. Among authors: turner jr. Am Heart J. 2013 Apr;165(4):477-88. doi: 10.1016/j.ahj.2013.01.002. Epub 2013 Feb 4. Am Heart J. 2013. PMID: 23537963

6

Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium.

Sager PT, Seltzer J, Turner JR, Anderson JL, Hiatt WR, Kowey P, Prochaska JJ, Stockbridge N, White WB. Sager PT, et al. Among authors: turner jr. Am Heart J. 2015 Apr;169(4):486-95. doi: 10.1016/j.ahj.2015.01.007. Epub 2015 Jan 15. Am Heart J. 2015. PMID: 25819855 Review.

7

The Cardiac Safety Research Consortium enters its second decade: An invitation to participate.

Turner JR, Kowey PR, Rodriguez I, Cabell CH, Gintant G, Green CL, Kunz BL, Mortara J, Sager PT, Stockbridge N, Wright TJ, Finkle J, Krucoff MW; Cardiac Safety Research Consortium. Turner JR, et al. Am Heart J. 2016 Jul;177:96-101. doi: 10.1016/j.ahj.2016.04.009. Epub 2016 Apr 23. Am Heart J. 2016. PMID: 27297854 Review.

8

Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium.

Seltzer JH, Turner JR, Geiger MJ, Rosano G, Mahaffey KW, White WB, Sabol MB, Stockbridge N, Sager PT. Seltzer JH, et al. Among authors: turner jr. Am Heart J. 2015 Feb;169(2):197-204. doi: 10.1016/j.ahj.2014.11.003. Epub 2014 Nov 10. Am Heart J. 2015. PMID: 25641528

9

Enabling social listening for cardiac safety monitoring: Proceedings from a drug information association-cardiac safety research consortium cosponsored think tank.

Seifert HA, Malik RE, Bhattacharya M, Campbell KR, Okun S, Pierce C, Terkowitz J, Turner JR, Krucoff MW, Powell GE. Seifert HA, et al. Among authors: turner jr. Am Heart J. 2017 Dec;194:107-115. doi: 10.1016/j.ahj.2017.08.021. Epub 2017 Sep 4. Am Heart J. 2017. PMID: 29223428 Review.

10

Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes.

Geiger MJ, Mehta C, Turner JR, Arbet-Engels C, Hantel S, Hirshberg B, Koglin J, Mendzelevski B, Sager PT, Shapiro D, Stewart M, Todaro TG, Gaydos B. Geiger MJ, et al. Among authors: turner jr. Ther Innov Regul Sci. 2015 Jan;49(1):50-64. doi: 10.1177/2168479014549860. Ther Innov Regul Sci. 2015. PMID: 30222452

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

885 results

Search Page